(PHR) Phreesia - NYSE
Sector: Healthcare | Industry: Health Information Services | Exchange: NYSE (USA) | Market Cap: 590m USD | Total Return: -67.4% in 12m
Avg Turnover: 14.2M
Qual. Beats: 0
Rev. Trend: 99.5%
Qual. Beats: 1
Warnings
Interest Coverage Ratio 0.8 is critical
Altman Z'' -1.44 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Phreesia, Inc. (PHR) operates a specialized software-as-a-service (SaaS) platform designed to automate patient intake and financial workflows for healthcare providers in the United States and Canada. The company’s suite includes AI-enabled appointment scheduling, referral management, and automated patient communication tools. Beyond software, Phreesia provides physical hardware, such as self-service kiosks and tablets, to facilitate on-site data capture and clinical documentation.
The business model relies on a dual-revenue stream consisting of subscription fees from healthcare organizations and transaction-based fees from its integrated payment processing solutions. In the Health Care Technology sector, high switching costs often provide established SaaS providers with significant client retention, as clinical data integration is complex to replicate. Phreesia serves a diverse client base ranging from ambulatory practices and large health systems to life sciences companies and government entities.
Investors can evaluate the long-term sustainability of these revenue streams by reviewing the fundamental data on ValueRay. Founded in 2005 and headquartered in Delaware, the company focuses on accelerating cash collections for providers while streamlining the digital patient experience.
- Life sciences engagement revenue growth drives high-margin subscription and media scalability
- Patient payment volume expansion accelerates recurring transaction processing fee income
- Operating leverage and cost discipline determine path to consistent GAAP profitability
- Increasing healthcare provider network density enhances long-term upsell and cross-sell potential
- Regulatory changes in data privacy impact pharmaceutical advertising and patient outreach efficacy
| Net Income: 9.18m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 4.70 > 1.0 |
| NWC/Revenue: 23.24% < 20% (prev 24.09%; Δ -0.86% < -1%) |
| CFO/TA 0.13 > 3% & CFO 86.0m > Net Income 9.18m |
| Net Debt (19.8m) to EBITDA (42.4m): 0.47 < 3 |
| Current Ratio: 1.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.0m) vs 12m ago 5.30% < -2% |
| Gross Margin: 65.81% > 18% (prev 68.02%; Δ -2.21% > 0.5%) |
| Asset Turnover: 92.93% > 50% (prev 108.5%; Δ -15.59% > 0%) |
| Interest Coverage Ratio: 0.83 > 6 (EBIT TTM 7.72m / Interest Expense TTM 9.32m) |
| A: 0.17 (Total Current Assets 267.3m - Total Current Liabilities 152.1m) / Total Assets 666.1m |
| B: -1.20 (Retained Earnings -796.2m / Total Assets 666.1m) |
| C: 0.01 (EBIT TTM 7.72m / Avg Total Assets 533.3m) |
| D: 1.17 (Book Value of Equity 359.1m / Total Liabilities 307.1m) |
| Altman-Z'' = -1.44 = CCC |
| DSRI: 1.16 (Receivables 143.3m/108.1m, Revenue 495.6m/434.5m) |
| GMI: 1.03 (GM 68.02% / 65.81%) |
| AQI: 1.41 (AQ_t 0.56 / AQ_t-1 0.40) |
| SGI: 1.14 (Revenue 495.6m / 434.5m) |
| TATA: -0.12 (NI 9.18m - CFO 86.0m) / TA 666.1m) |
| Beneish M = -2.53 (Cap -4..+1) = A |
As of June 11, 2026, the stock is trading at USD 9.14 with a total of 830,412 shares traded.
Over the past week, the price has changed by -5.28%,
over one month by -4.49%,
over three months by -22.21% and
over the past year by -67.38%.
Phreesia has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy PHR.
- StrongBuy: 10
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.3 | 56.2% |
P/E Trailing = 59.625
P/E Forward = 12.9199
P/S = 1.1899
P/B = 1.668
Revenue TTM = 495.6m USD
EBIT TTM = 7.72m USD
EBITDA TTM = 42.4m USD
Long Term Debt = 85.3m USD (from longTermDebt, last quarter)
Short Term Debt = 6.36m USD (from shortTermDebt, last quarter)
Debt = 94.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.95m
Net Debt = 19.8m USD (calculated: Debt 94.5m - CCE 74.7m)
Enterprise Value = 609.5m USD (589.7m + Debt 94.5m - CCE 74.7m)
Interest Coverage Ratio = 0.83 (Ebit TTM 7.72m / Interest Expense TTM 9.32m)
EV/FCF = 8.27x (Enterprise Value 609.5m / FCF TTM 73.7m)
FCF Yield = 12.10% (FCF TTM 73.7m / Enterprise Value 609.5m)
FCF Margin = 14.88% (FCF TTM 73.7m / Revenue TTM 495.6m)
Net Margin = 1.85% (Net Income TTM 9.18m / Revenue TTM 495.6m)
Gross Margin = 65.81% ((Revenue TTM 495.6m - Cost of Revenue TTM 169.5m) / Revenue TTM)
Gross Margin QoQ = 59.21% (prev 68.21%)
Tobins Q-Ratio = 0.91 (Enterprise Value 609.5m / Total Assets 666.1m)
Interest Expense / Debt = 9.86% (Interest Expense 9.32m / Debt 94.5m)
Taxrate = 37.26% (1.76m / 4.72m)
NOPAT = 4.85m (EBIT 7.72m * (1 - 37.26%))
Current Ratio = 1.76 (Total Current Assets 267.3m / Total Current Liabilities 152.1m)
Debt / Equity = 0.26 (Debt 94.5m / totalStockholderEquity, last quarter 359.1m)
Debt / EBITDA = 0.47 (Net Debt 19.8m / EBITDA 42.4m)
Debt / FCF = 0.27 (Net Debt 19.8m / FCF TTM 73.7m)
Total Stockholder Equity = 328.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.72% (Net Income 9.18m / Total Assets 666.1m)
RoE = 2.79% (Net Income TTM 9.18m / Total Stockholder Equity 328.7m)
RoCE = 1.87% (EBIT 7.72m / Capital Employed (Equity 328.7m + L.T.Debt 85.3m))
RoIC = 0.98% (NOPAT 4.85m / Invested Capital 495.6m)
WACC = 11.02% (E(589.7m)/V(684.2m) * Re(11.79%) + D(94.5m)/V(684.2m) * Rd(9.86%) * (1-Tc(0.37)))
Discount Rate = 11.79% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 5.88%
[DCF] Terminal Value 69.85% ; FCFF base≈54.4m ; Y1≈62.4m ; Y5≈91.8m
[DCF] Fair Price = 14.86 (EV 938.3m - Net Debt 19.8m = Equity 918.5m / Shares 61.8m; r=11.02% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.48 | # QB: 0
Revenue Correlation: 99.51 | Revenue CAGR: 16.84% | SUE: 3.22 | # QB: 1
EPS current Quarter (2026-07-31): EPS=0.32 | Chg30d=-2.88% | Revisions=+17% | Analysts=10
EPS next Quarter (2026-10-31): EPS=0.35 | Chg30d=-9.88% | Revisions=-38% | Analysts=10
EPS current Year (2027-01-31): EPS=1.32 | Chg30d=-8.56% | Revisions=-33% | GrowthEPS=+2.4% | GrowthRev=+7.2%
EPS next Year (2028-01-31): EPS=1.60 | Chg30d=-7.68% | Revisions=-8% | GrowthEPS=+20.8% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: -38%